Artivion (NYSE:AORT) Insider Sells $141,827.07 in Stock

Artivion, Inc. (NYSE:AORT) insider John Davis sold 3,773 shares of the firm’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $37.59, for a total value of $141,827.07. Following the completion of the transaction, the insider owned 190,943 shares in the company, valued at $7,177,547.37. The trade was a 1.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Artivion Price Performance

AORT traded up $0.31 on Wednesday, hitting $35.66. 300,261 shares of the stock were exchanged, compared to its average volume of 399,410. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of 178.32 and a beta of 1.59. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.53 and a quick ratio of 2.62. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.25. The business has a 50-day moving average of $42.51 and a two-hundred day moving average of $43.14.

Artivion (NYSE:AORT) last issued its earnings results on Thursday, February 12th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. The firm’s revenue was up 19.2% compared to the same quarter last year. Sell-side analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Citizens Jmp raised their price objective on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Canaccord Genuity Group dropped their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a report on Friday, February 13th. Finally, Oppenheimer restated an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Artivion currently has an average rating of “Moderate Buy” and a consensus target price of $48.97.

Hedge Funds Weigh In On Artivion

A number of institutional investors and hedge funds have recently bought and sold shares of AORT. Invesco Ltd. increased its holdings in Artivion by 211.9% in the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after purchasing an additional 748,119 shares during the period. XTX Topco Ltd bought a new stake in shares of Artivion in the 4th quarter valued at about $746,000. Susquehanna Portfolio Strategies LLC increased its stake in shares of Artivion by 21.5% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 40,542 shares of the company’s stock valued at $1,849,000 after buying an additional 7,186 shares during the period. Occudo Quantitative Strategies LP acquired a new stake in shares of Artivion in the fourth quarter valued at about $248,000. Finally, Millennium Management LLC raised its position in shares of Artivion by 1.0% during the fourth quarter. Millennium Management LLC now owns 91,816 shares of the company’s stock worth $4,188,000 after acquiring an additional 893 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.